CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2013 Gastrointestinal Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Yao on Everolimus in Advanced Pancreatic NET
Dr. Ruff Analyzes Overall Survival in the VELOUR Trial
Dr. Kim on the Investigation of Regorafenib in mCRC
Oncology Conference Articles
Side Effects With Regorafenib Occur Early and Tend to Taper
The incidence of adverse effects with regorafenib in metastatic colorectal cancer is highest during the first treatment cycle and then diminishes over time.
Similar Benefit, Lower Toxicity Found With Capecitabine- Versus Gemcitabine-based Chemoradiation in Pancreatic Cancer
Capecitabine produces similar local disease control with lower toxicity versus gemcitabine when combined with radiotherapy following induction chemotherapy in patients with locally advanced pancreatic cancer.
Bevacizumab Plus FOLFOXIRI May Offer New First-Line Option in mCRC
FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.
Complete Neoadjuvant Chemotherapy May Offer New Framework for Treating Rectal Cancer
Complete neoadjuvant treatment may represent a well-tolerated alternative to the current standard treatment sequence of adjuvant chemotherapy following chemoradiation and surgery.
Nab-Paclitaxel Plus Gemcitabine Could Be New 'Backbone' of Therapy for Metastatic Pancreatic Cancer
Adding nab-paclitaxel to gemcitabine improves survival compared with gemcitabine alone in patients with metastatic pancreatic cancer.
Ramucirumab Moderately Boosts Survival in Advanced Gastric Cancer
Ramucirumab significantly extended overall survival as a second-line agent in patients with metastatic gastric or gastroesophageal junction adenocarcinoma that progressed on first-line therapy.
Extended Survival Benefit With Zaltrap Seen in Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.
Adjuvant S-1 Chemotherapy Bests Gemcitabine in Asian Patients With Pancreatic Cancer
Adjuvant chemotherapy with the oral fluoropyrimidine S-1 improved survival versus standard postoperative gemcitabine in Asian patients with pancreatic cancer, according to an interim analysis from a phase III trial conducted in Japan.
Gene Profiling of Circulating Tumor Cells May Predict Treatment Response in Pancreatic Cancer
A simple blood draw could lead to life-prolonging adjustments in treatment for patients with pancreatic cancer, the authors of a study have found.
Colorectal Cancer Prognosis and Response to Chemotherapy Vary by Molecular Subtype
Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.
Second-Line Docetaxel Improves Survival and Quality of Life in Patients with Advanced Esophageal and Stomach Cancers
Patients with advanced esophagogastric adenocarcinoma who received docetaxel as a second-line therapy experienced a longer period of overall survival as well as a better quality of life compared with patients who received active symptom control.
Surgery Following Imatinib Boosts Survival for GIST Patients
A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.
FDA Approval in HCC, Breakthrough Designation in MCL, and More
Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer
Treatment Goals in Refractory mCRC
FDA Approves Third Trastuzumab Biosimilar
Olaratumab Falls Short in Phase III Soft Tissue Sarcoma Trial
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.